After various media reports claimed that Bharat Biotech's Covaxin is yet not on the WHO's Emergency Use Listing (EUL) and nations like USA, Canada, Australia, Ireland, and the European Union do not recognize people vaccinated with Covaxin, the company today said that it has submitted almost all the documents required by WHO for the listing.
Earlier today, Soumya Pandey, Country Advisor of University of Limerick said, “Covaxin is not on the approved list, which means students will not be exempt from mandatory hotel quarantine which is very expensive – to stay in a hotel for 14 days.”
However, Bharat Biotech addressed the concerned authority and said, “The company has submitted 90 percent of the documents required for WHO’s authorization for Emergency Use Listing.”
The company added, “The remaining is expected to be submitted in June and said that it is confident of getting clearance subsequently.”
Bharat Biotech also said that it was in the final stage of submitting documents in Brazil and Hungary after “extensive bilateral consultations” with both countries.
The company said, “BBIL is also in the final stages of negotiation with FDA of the USA for conducting small-scale phase-III clinical trials in the USA.”
Bharat Biotech’s Covaxin has received regulatory approvals from 11 countries and seven countries have shown interest in the technology transfer and production of the Covid shot.
Bharat Biotech said, “It is important to note that no country has instituted a vaccine passport. Countries have their own requirements for approval, which in most involves travel by carrying a negative RT-PCR report.”